Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 888 dose-ranging study in idiopathic pulmonary fibrosis
NL-OMON37285Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carlumab in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Rate of percent change in FVC through Week 52. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
carlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON37285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37285.